Regeneron Pharmaceuticals Inc (REGN) Position Increased by Central Bank & Trust Co.

Central Bank & Trust Co. increased its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 7.0% during the first quarter, HoldingsChannel reports. The institutional investor owned 11,091 shares of the biopharmaceutical company’s stock after buying an additional 721 shares during the quarter. Central Bank & Trust Co.’s holdings in Regeneron Pharmaceuticals were worth $4,554,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in REGN. Bank of New York Mellon Corp lifted its stake in Regeneron Pharmaceuticals by 1.3% in the third quarter. Bank of New York Mellon Corp now owns 604,944 shares of the biopharmaceutical company’s stock worth $244,420,000 after acquiring an additional 7,520 shares during the last quarter. BlueMountain Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 89.8% in the third quarter. BlueMountain Capital Management LLC now owns 1,919 shares of the biopharmaceutical company’s stock valued at $775,000 after buying an additional 908 shares during the period. Mackenzie Financial Corp increased its stake in shares of Regeneron Pharmaceuticals by 17.5% during the third quarter. Mackenzie Financial Corp now owns 1,508 shares of the biopharmaceutical company’s stock worth $609,000 after purchasing an additional 225 shares during the period. Macquarie Group Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 4.1% during the third quarter. Macquarie Group Ltd. now owns 70,330 shares of the biopharmaceutical company’s stock worth $28,416,000 after purchasing an additional 2,790 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 63.6% during the third quarter. AQR Capital Management LLC now owns 184,181 shares of the biopharmaceutical company’s stock worth $74,416,000 after purchasing an additional 71,623 shares during the period. 66.97% of the stock is currently owned by hedge funds and other institutional investors.

In other news, major shareholder Sanofi sold 131,115 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 12.42% of the company’s stock.

Shares of REGN stock traded down $2.62 during mid-day trading on Monday, hitting $330.72. The company’s stock had a trading volume of 20,468 shares, compared to its average volume of 786,808. Regeneron Pharmaceuticals Inc has a 52 week low of $281.89 and a 52 week high of $442.00. The company has a current ratio of 4.47, a quick ratio of 3.67 and a debt-to-equity ratio of 0.08. The firm has a market cap of $36.35 billion, a PE ratio of 16.67, a price-to-earnings-growth ratio of 1.29 and a beta of 1.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The firm had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.73 billion. During the same period last year, the company posted $5.23 EPS. The business’s quarterly revenue was up 21.9% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current year.

REGN has been the topic of a number of recent research reports. Guggenheim lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $466.00 to $425.00 in a research note on Friday, February 22nd. TheStreet raised Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, January 17th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price objective on the stock in a report on Thursday, February 7th. BidaskClub lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 7th. Finally, Cowen reaffirmed a “hold” rating and set a $385.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, January 7th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $413.94.

WARNING: This report was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/22/regeneron-pharmaceuticals-inc-regn-position-increased-by-central-bank-trust-co.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Institutional Investors

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.